Sirolimus versus paclitaxel coronary stents in clinical practice

Catheterization and Cardiovascular Interventions

Volumn 77, Issue 1, 2011, Pages 5-12

  Millauer, Niklas ^a   Jüni, Peter ^b,c   Hofmann, Alexandra ^a   Wandel, Simon ^b,c   Bhambhani, Anupham ^a   Billinger, Michael ^a   Urwyler, Niklaus ^a   Wenaweser, Peter ^a   Hellige, Gerrit ^a   Cook, Stéphane ^a   Vogel, Rolf ^a   Togni, Mario ^a   Seiler, Christian ^a   Meier, Bernhard ^a   Windecker, Stephan ^a,b  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

coronary artery disease; percutaneous intervention; stents

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYPHER; HEPARIN; PACLITAXEL; RAPAMYCIN; UNCLASSIFIED DRUG;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; CORONARY STENT; DEATH; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERPLASIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; STENT THROMBOSIS;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; DIABETES MELLITUS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SIROLIMUS; SWITZERLAND; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 78650632317     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22597     Document Type: Article

References (29)

1. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
2. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
3. Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005; 353: 653-662. (Pubitemid 41175673)
4. Morice MC, Colombo A, Meier B, et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: The REALITY trial: A randomized controlled trial. JAMA 2006; 295: 895-904.
5. Dibra A, Kastrati A, Mehilli J, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663-670.
6. Tomai F, Reimers B, De Luca L, et al. Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: A prospective, randomized, multicenter study. Diabetes Care 2008; 31: 15-19.
7. Lee SW, Park SW, Kim YH, et al. A randomized comparison of sirolimus- versus Paclitaxel-eluting stent implantation in patients with diabetes mellitus. J Am Coll Cardiol 2008; 52: 727-733.
8. Goy JJ, Stauffer JC, Siegenthaler M, et al. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: The TAXi trial. J Am Coll Cardiol 2005; 45: 308-311.
9. Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: A randomized controlled trial. JAMA 2005; 293: 165-171.
10. Kim YH, Park SW, Lee SW, et al. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation 2006; 114: 2148-2153.
11. Petronio AS, De Carlo M, Branchitta G, et al. Randomized comparison of sirolimus and paclitaxel drug-eluting stents for long lesions in the left anterior descending artery: An intravascular ultrasound study. J Am Coll Cardiol 2007; 49: 539-546.
12. Simonton CA, Brodie B, Cheek B, et al. Comparative clinical outcomes of paclitaxel- and sirolimus-eluting stents: Results from a large prospective multicenter registry-STENT group. J Am Coll Cardiol 2007; 50: 1214-1222.
13. Cosgrave J, Melzi G, Corbett S, et al. Comparable clinical outcomes with paclitaxel- and sirolimus-eluting stents in unrestricted contemporary practice. J Am Coll Cardiol 2007; 49: 2320-2328.
14. Elezi S, Dibra A, Mehilli J, et al. Vessel size and outcome after coronary drug-eluting stent placement: Results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. J Am Coll Cardiol 2006; 48: 1304-1309.
15. Saia F, Piovaccari G, Manari A, et al. Clinical outcomes for sirolimus-eluting stents and polymer-coated paclitaxel-eluting stents in daily practice: Results from a large multicenter registry. J Am Coll Cardiol 2006; 48: 1312-1318.
16. Kaiser C, Brunner-La Rocca HP, Buser PT, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: Randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005; 366: 921-929.
17. Galloe AM, Thuesen L, Kelbaek H, et al. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: The SORT OUT II randomized trial. JAMA 2008; 299: 409-416.
18. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
19. Juni P, Altman DG, Egger M,. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001; 323: 42-46.
20. Vandenbroucke JP, Psaty BM,. Benefits and risks of drug treatments: How to combine the best evidence on benefits with the best data about adverse effects. JAMA 2008; 300: 2417-2419.
21. Schomig A, Dibra A, Windecker S, et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1373-1380.
22. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis. Lancet 2007; 370: 937-948.
23. Mauri L, Orav EJ, Kuntz RE,. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation 2005; 111: 3435-3442. (Pubitemid 40923397)
24. Pocock SJ, Lansky AJ, Mehran R, et al. Angiographic surrogate end points in drug-eluting stent trials: A systematic evaluation based on individual patient data from 11 randomized, controlled trials. J Am Coll Cardiol 2008; 51: 23-32.
25. Serruys PW, Ruygrok P, Neuzner J, et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: The SPIRIT II trial. EuroIntervention 2006; 2: 286-294.
26. Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: A randomized trial. JAMA 2008; 299: 1903-1913.
27. Billinger M, Beutler J, Taghetchian KR, et al. Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients. Eur Heart J 2008; 29: 718-725.
28. Mahmud E, Bromberg-Marin G, Palakodeti V, et al. Clinical efficacy of drug-eluting stents in diabetic patients: A meta-analysis. J Am Coll Cardiol 2008; 51: 2385-2395.
29. Stettler C, Allemann S, Wandel S, et al. Drug eluting and bare metal stents in people with and without diabetes: Collaborative network meta-analysis. BMJ 2008; 337: a1331.